Anti-V3 Humanized Antibody KD-247 Effectively Suppresses Ex Vivo Generation of Human Immunodeficiency Virus Type 1 and Affords Sterile Protection of Monkeys against a Heterologous Simian/Human Immunodeficiency Virus Infection
Open Access
- 1 June 2006
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 80 (11) , 5563-5570
- https://doi.org/10.1128/jvi.02095-05
Abstract
In an accompanying report (Y. Eda, M. Takizawa, T. Murakami, H. Maeda, K. Kimachi, H. Yonemura, S. Koyanagi, K. Shiosaki, H. Higuchi, K. Makizumi, T. Nakashima, K. Osatomi, S. Tokiyoshi, S. Matsushita, N. Yamamoto, and M. Honda, J. Virol. 80:5552-5562, 2006), we discuss our production of a high-affinity humanized monoclonal antibody, KD-247, by sequential immunization with V3 peptides derived from human immunodeficiency virus type 1 (HIV-1) clade B primary isolates. Epitope mapping revealed that KD-247 recognized the Pro-Gly-Arg V3 tip sequence conserved in HIV-1 clade B isolates. In this study, we further demonstrate that in vitro, KD-247 efficiently neutralizes CXCR4- and CCR5-tropic primary HIV-1 clade B and clade B′ with matching neutralization sequence motifs but does not neutralize sequence-mismatched clade B and clade E isolates. Monkeys were provided sterile protection against heterologous simian/human immunodeficiency virus challenge by the passive transfer of a single high dose (45 mg per kg of body weight) of KD-247 and afforded partial protection by lower antibody doses (30 and 15 mg per kg). Protective neutralization endpoint titers in plasma at the time of virus challenge were 1:160 in animals passively transferred with a high dose of the antibody. The antiviral efficacy of the antibody was further confirmed by its suppression of the ex vivo generation of primary HIV-1 quasispecies in peripheral blood mononuclear cell cultures from HIV-infected individuals. Therefore, KD-247 promises to be a valuable tool not only as a passive immunization antibody for the prevention of HIV infection but also as an immunotherapy for the suppression of HIV in phenotype-matched HIV-infected individuals.Keywords
This publication has 64 references indexed in Scilit:
- Sequential Immunization with V3 Peptides from Primary Human Immunodeficiency Virus Type 1 Produces Cross-Neutralizing Antibodies against Primary Isolates with a Matching Narrow-Neutralization Sequence MotifJournal of Virology, 2006
- Vaccination of Rhesus Macaques with RecombinantMycobacterium bovisBacillus Calmette-Guérin Env V3 Elicits Neutralizing Antibody-Mediated Protection against Simian-Human Immunodeficiency Virus with a Homologous but Not a Heterologous V3 MotifJournal of Virology, 2005
- Antibody neutralization and escape by HIV-1Nature, 2003
- Isolation and Characterization of an Infectious HIV Type 1 Molecular Clone from a Patient with Primary InfectionAIDS Research and Human Retroviruses, 2002
- Correlation of Titer of Antibody to Principal Neutralizing Domain of HIVMNStrain with Disease Progression in Japanese Hemophiliacs Seropositive for HIV Type 1AIDS Research and Human Retroviruses, 1997
- Utility of SHIV for Testing HIV-1 Vaccine Candidates in MacaquesJAIDS Journal of Acquired Immune Deficiency Syndromes, 1996
- Neutralization of HIV-1AIDS Research and Human Retroviruses, 1994
- Characteristics of the Principal Neutralizing Determinant of HIV-1 Prevalent in JapanAIDS Research and Human Retroviruses, 1991
- HIV-1 Neutralizing Monoclonal Antibodies Induced by a Synthetic PeptideAIDS Research and Human Retroviruses, 1990
- Conserved Sequence and Structural Elements in the HIV-1 Principal Neutralizing DeterminantScience, 1990